Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > BUSINESS
BUSINESS
- 20 Companies Review Risk Countermeasures After Earthquake, Novartis Looks into MR Standards of Behavior: Jiho Survey
March 9, 2012
- Novartis Voluntarily Recalls 720,000 Diovan Tablets due to Insect Contamination
March 9, 2012
- The Earthquake-Hit Regions Today 3: “Inventory”as an Edge, Changes in Risk Management
March 9, 2012
- Daiichi Sankyo to Integrate Global, Japan Business Management Functions into Four-Division Structure
March 8, 2012
- Daiichi Sankyo Says Mr Yoshiwaka to Become Espha President
March 8, 2012
- MTPC Enters into Agreement for Joint Research of New Vaccines with Canadian Company
March 8, 2012
- US FDA Does Not Approve Additional Indication of AML for Eisai’s Dacogen
March 8, 2012
- “Absolutely No Intention” of Moving Headquarters from Osaka: President Teshirogi of Shionogi
March 8, 2012
- The Earthquake-Hit Regions Today 2: “Irregular Visits” Still Continue for MRs Faced With “Fukushima”
March 8, 2012
- MTPC, Daiichi Sankyo Form Strategic Alliance to Jointly Market 2 Diabetes Treatments
March 7, 2012
- Use of Aricept Generics Is Likely to Expand to Nursing Homes: Pharmacist Survey
March 7, 2012
- The Earthquake-Hit Regions Today 1: Difficulties in Securing Pharmacists, Need for Long Sustained Support
March 7, 2012
- Price Reduction Rates for 4 Major Generics Manufacturers at 8.9% to 12.2%: Jiho Survey
March 7, 2012
- Takeda US Subsidiary Millennium Begins International PIII Trial on Alisertib
March 7, 2012
- Long-Listed Drugs Account for Over 60% of Eisai’s Sales: Jiho Survey
March 7, 2012
- Worldwide Sales by Biopharmaceutical Contract Manufacturers Down Slightly in 2010 at US$3.4 Billion: Seed Planning
March 7, 2012
- Eisai to See 11%+, Lilly Japan 8-9% Average Price Reduction in FY2012 NHI Price Revision: Jiho Survey
March 6, 2012
- Nomura Securities Report Says Takeda’s TAK-875 Hoped to Become Blockbuster
March 6, 2012
- Pfizer to Outsource Clinical Trials in Japan to 2 CROs from April
March 6, 2012
- Share of Aricept Generic to Increase by Some 20% in Future: Eisai Senior Vice President Naoe
March 5, 2012
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…